BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
NYSE:BIO.B • US0905721082
261.83 USD
+4.78 (+1.86%)
Last: Feb 18, 2026, 08:16 PM
Taking everything into account, BIO.B scores 4 out of 10 in our fundamental rating. BIO.B was compared to 58 industry peers in the Life Sciences Tools & Services industry. BIO.B has an excellent financial health rating, but there are some minor concerns on its profitability. BIO.B has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- BIO.B had positive earnings in the past year.
- BIO.B had a positive operating cash flow in the past year.
- In the past 5 years BIO.B reported 4 times negative net income.
- Of the past 5 years BIO.B 4 years had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -6.97%, BIO.B is in line with its industry, outperforming 53.45% of the companies in the same industry.
- The Return On Equity of BIO.B (-10.03%) is comparable to the rest of the industry.
- With a decent Return On Invested Capital value of 2.26%, BIO.B is doing good in the industry, outperforming 63.79% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 12.04%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- Looking at the Operating Margin, with a value of 10.27%, BIO.B is in the better half of the industry, outperforming 70.69% of the companies in the same industry.
- In the last couple of years the Operating Margin of BIO.B has remained more or less at the same level.
- BIO.B has a better Gross Margin (52.42%) than 63.79% of its industry peers.
- In the last couple of years the Gross Margin of BIO.B has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO.B is destroying value.
- There is no outstanding debt for BIO.B. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 3.15 indicates that BIO.B is not in any danger for bankruptcy at the moment.
- BIO.B has a Altman-Z score of 3.15. This is in the better half of the industry: BIO.B outperforms 70.69% of its industry peers.
- The Debt to FCF ratio of BIO.B is 3.57, which is a good value as it means it would take BIO.B, 3.57 years of fcf income to pay off all of its debts.
- BIO.B's Debt to FCF ratio of 3.57 is fine compared to the rest of the industry. BIO.B outperforms 77.59% of its industry peers.
- BIO.B has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.18, BIO.B is in line with its industry, outperforming 58.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.15 |
ROIC/WACC0.21
WACC10.53%
2.3 Liquidity
- A Current Ratio of 5.44 indicates that BIO.B has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 5.44, BIO.B belongs to the top of the industry, outperforming 86.21% of the companies in the same industry.
- BIO.B has a Quick Ratio of 3.94. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of BIO.B (3.94) is better than 68.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- BIO.B shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
- Measured over the past years, BIO.B shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.19% on average per year.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
3.2 Future
- BIO.B is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.38% yearly.
- BIO.B is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.60% yearly.
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue Next Year1.61%
Revenue Next 2Y2.36%
Revenue Next 3Y2.35%
Revenue Next 5Y1.6%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 26.39, the valuation of BIO.B can be described as expensive.
- 68.97% of the companies in the same industry are more expensive than BIO.B, based on the Price/Earnings ratio.
- BIO.B is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.09, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 25.54, which means the current valuation is very expensive for BIO.B.
- Based on the Price/Forward Earnings ratio, BIO.B is valued a bit cheaper than the industry average as 70.69% of the companies are valued more expensively.
- BIO.B is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 27.98, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.39 | ||
| Fwd PE | 25.54 |
4.2 Price Multiples
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of BIO.B indicates a rather cheap valuation: BIO.B is cheaper than 82.76% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.97 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO.B does not grow enough to justify the current Price/Earnings ratio.
- BIO.B's earnings are expected to decrease with -3.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)7.92
PEG (5Y)N/A
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
5. Dividend
5.1 Amount
- No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:BIO.B (2/18/2026, 8:16:08 PM)
261.83
+4.78 (+1.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners92.92%
Inst Owner Change-0.24%
Ins Owners8.18%
Ins Owner ChangeN/A
Market Cap7.06B
Revenue(TTM)N/A
Net Income(TTM)-675.90M
Analysts76
Price Target359.2 (37.19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)-1.2%
PT rev (3m)-2.76%
EPS NQ rev (1m)-1.46%
EPS NQ rev (3m)-4.14%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)-0.9%
Revenue NQ rev (1m)-0.65%
Revenue NQ rev (3m)-1.79%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.39 | ||
| Fwd PE | 25.54 | ||
| P/S | 2.76 | ||
| P/FCF | 20.97 | ||
| P/OCF | 14.37 | ||
| P/B | 1.05 | ||
| P/tB | 1.22 | ||
| EV/EBITDA | N/A |
EPS(TTM)9.92
EY3.79%
EPS(NY)10.25
Fwd EY3.92%
FCF(TTM)12.48
FCFY4.77%
OCF(TTM)18.22
OCFY6.96%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)7.92
PEG (5Y)N/A
Graham Number236.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.15 |
F-Score5
WACC10.53%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
Revenue Next Year1.61%
Revenue Next 2Y2.36%
Revenue Next 3Y2.35%
Revenue Next 5Y1.6%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.36%
EBIT Next 3Y14.58%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B.
Can you provide the valuation status for BIO-RAD LABORATORIES -CL B?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 4 / 10.
How financially healthy is BIO-RAD LABORATORIES -CL B?
The financial health rating of BIO-RAD LABORATORIES -CL B (BIO.B) is 7 / 10.